mstockstill on DSK4VPTVN1PROD with NOTICES


Federal Register / Vol. 76, No. 111 / Thursday, June 9, 2011 / Notices 33763 

designated the following class of 

employees as an addition to the SEC: 

All Atomic Weapons Employer employees 

who worked in any building at the Wah 

Chang facility in Albany, Oregon, for the 

operational period from January 1, 1971 

through December 31, 1972, for a number of 

work days aggregating at least 250 work days, 

occurring either solely under this 

employment or in combination with work 

days within the parameters established for 

one or more other classes of employees 

included in the Special Exposure Cohort. 

This designation became effective on 

May 29, 2011, as provided for under 42 

U.S.C. 7384l(14)(C). Hence, beginning 

on May 29, 2011, members of this class 

of employees, defined as reported in 

this notice, became members of the 

Special Exposure Cohort. 

FOR FURTHER INFORMATION CONTACT: 

Stuart L. Hinnefeld, Director, Division 

of Compensation Analysis and Support, 

National Institute for Occupational 

Safety and Health (NIOSH), 4676 

Columbia Parkway, MS C–46, 

Cincinnati, OH 45226, Telephone 877– 

222–7570. Information requests can also 

be submitted by e-mail to dcas@cdc.gov. 

John Howard, 

Director, National Institute for Occupational 

Safety and Health. 

[FR Doc. 2011–14355 Filed 6–8–11; 8:45 am] 

BILLING CODE 4163–19–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Final Effect of Designation of a Class 

of Employees for Addition to the 

Special Exposure Cohort 

AGENCY: National Institute for 

Occupational Safety and Health 

(NIOSH), Department of Health and 

Human Services (HHS). 

ACTION: Notice. 

SUMMARY: HHS gives notice concerning 

the final effect of the HHS decision to 

designate a class of employees from the 

Norton Company, Worcester, 

Massachusetts, as an addition to the 

Special Exposure Cohort (SEC) under 

the Energy Employees Occupational 

Illness Compensation Program Act of 

2000. On April 29, 2011, as provided for 

under 42 U.S.C. 7384q(b), the Secretary 

of HHS designated the following class of 

employees as an addition to the SEC: 

All atomic weapons employees who 

worked in any building or area at the facility 

owned by the Norton Co. (or a subsequent 

owner) in Worcester, Massachusetts, during 

the period from January 1, 1958 through 

October 10, 1962, for a number of work days 

aggregating at least 250 work days, occurring 

either solely under this employment or in 

combination with work days within the 

parameters established for one or more other 

classes of employees included in the Special 

Exposure Cohort. 

This designation became effective on 

May 29, 2011, as provided for under 42 

U.S.C. 7384l(14)(C). Hence, beginning 

on May 29, 2011, members of this class 

of employees, defined as reported in 

this notice, became members of the 

Special Exposure Cohort. 

FOR FURTHER INFORMATION CONTACT: 

Stuart L. Hinnefeld, Director, Division 

of Compensation Analysis and Support, 

National Institute for Occupational 

Safety and Health (NIOSH), 4676 

Columbia Parkway, MS C–46, 

Cincinnati, OH 45226, Telephone 877– 

222–7570. Information requests can also 

be submitted by e-mail to 

DCAS@CDC.GOV. 

John Howard, 

Director, National Institute for Occupational 

Safety and Health. 

[FR Doc. 2011–14356 Filed 6–8–11; 8:45 am] 

BILLING CODE 4163–19–P 

DEPARTMENT OF HEALTH AND 


HUMAN SERVICES 


Office of the Secretary 


Findings of Misconduct in Science/ 


Research Misconduct 


AGENCY: Office of the Secretary, HHS. 


ACTION: Notice. 


SUMMARY: Notice is hereby given that on 

May 16, 2011, the Department of Health 

and Human Services (HHS) Debarring 

Official, on behalf of the Secretary of 

HHS, issued a final notice of debarment 

based on the misconduct in science and 

research misconduct findings of the 

Office of Research Integrity (ORI) in the 

following case: 

Philippe Bois, Ph.D., St. Jude 

Children’s Research Hospital: Based on 

the findings of an investigation report 

by St. Jude Children’s Research Hospital 

(St. Jude) and additional analysis 

conducted by ORI during its oversight 

review, ORI found that Philippe Bois, 

Ph.D., former postdoctoral fellow, 

Department of Biochemistry, St. Jude, 

engaged in misconduct in science and 

research misconduct in research funded 

by National Institute of General Medical 

Sciences (NIGMS), National Institutes of 

Health (NIH), grant R01 GM071596, and 

National Cancer Institute (NCI), NIH, 

grants P30 CA021765, P01 CA071907, 

R01 CA072996, and R01 CA100603. 

ORI found that the Respondent 

knowingly and intentionally falsified 

data reported in two (2) papers: 

1. Bois, P.R., Izeradjene, K., Houghton, 

P.J., Cleveland, J.L., Houghton, J.A., 

& Grosveld, C.G. ‘‘FOXO1a acts as a 

selective tumor suppressor in 

alveolar rhabdomyosarcoma.’’ J. 

Cell. Biol. 170:903–912, September 

2005 (hereafter referred to as ‘‘JCB 

2005’’); and 

2. Bois, P.R., Borgon, R.A., Vornhein, C., 

& Izard, T. ‘‘Structural dynamics of 

a-actinin-vinculin interactions.’’ 

Mol. Cell. Biol. 25:6112–6122, July 

2005 (hereafter referred to as ‘‘MCB 

2005’’). 

Specifically, ORI found: 

• Respondent committed misconduct 

in science and research misconduct by 

knowingly and intentionally falsely 

reporting in Figure 1A of JCB 2005 that 

FOXO1a was not expressed in cell 

lysates from alveolar 

rhabdomyosarcoma (ARMS) tumor 

biopsies, by selecting a specific FOXO1a 

immunoblot to show the desired result. 

• Respondent engaged in misconduct 

in science and research misconduct by 

falsifying data presented in Figure 4B of 

MCB 2005 showing SDS–PAGE for 

papain digestion of VBS3 and aVBS, by 

falsely labeling lane 1 to represent 

papain only digestion, by falsely 

labeling lane 5 to represent papain 

digestion of the aVBS peptide, and by 

falsely inserting a band in lane 3 to 

represent the aVBS peptide. 

ORI issued a charge letter 

enumerating the above findings of 

misconduct in science and proposing 

HHS administrative actions. Dr. Bois 

subsequently requested a hearing before 

an Administrative Law Judge (ALJ) of 

the Departmental Appeals Board (DAB) 

to dispute these findings. ORI moved to 

dismiss Dr. Bois’ hearing request. On 

May 16, 2011, the ALJ of the DAB ruled 

in ORI’s favor and dismissed Dr. Bois’ 

hearing request. The ALJ found that Dr. 

Bois had not raised a genuine dispute 

over facts or law material to the findings 

of research misconduct and dismissed 

the hearing request pursuant to 42 CFR 

93.504(a)(2), (3). 

Thus, the misconduct in science and 

research misconduct findings set forth 

above became effective, and the 

following administrative actions have 

been implemented for a period of three 

(3) years, beginning on May 26, 2011: 

(1) Dr. Bois is debarred from 

eligibility for any contracting or 

subcontracting with any agency of the 

United States Government and from 

eligibility for, or involvement in, 

nonprocurement programs of the United 

States Government, referred to as 

‘‘covered transactions,’’ pursuant to 

HHS’ Implementation of OMB 

Guidelines to Agencies on